8-K: Zura Bio Highlights Dual-Pathway Biologics and Clinical Milestones at Jefferies Global Healthcare Conference

Zura Bio Limited presented an updated corporate overview at the Jefferies Global Healthcare Conference, emphasizing its pipeline of dual-pathway biologic candidates for autoimmune and inflammatory diseases, with key Phase 2 data expected in 2026.

Summary

• Zura Bio Limited (ZURA) provided an updated corporate presentation at the Jefferies Global Healthcare Conference on June 4, 2025, focusing on its pipeline of dual-pathway biologic candidates for autoimmune and inflammatory diseases.
• The company's lead product candidate, tibulizumab (ZB-106), is a bispecific antibody targeting both B cell activating factor (BAFF) and interleukin-17A (IL-17A), aiming to address the complexity of autoimmune diseases.
• Tibulizumab is currently being evaluated in two ongoing Phase 2 clinical trials: TibuSURE for adults with systemic sclerosis (SSc) and TibuSHIELD for adults with hidradenitis suppurativa (HS).
• Topline data from the TibuSURE SSc trial is anticipated in Q2 2026, and from the TibuSHIELD HS trial in Q3 2026.
• Zura Bio also has other pipeline candidates, including crebankitug (ZB-168), an anti-IL-7R antibody, and torudokimab (ZB-880), an anti-IL-33 antibody.
• The company strengthened its leadership team in 2024 with the appointment of Rob Lisicki as CEO and Dr. Kiran Nistala as CMO.
• Zura Bio raised $112.5 million through a private placement in 2024, and its cash runway is projected to extend through 2027.

Sentiment

Score: 8

Explanation: The document presents a highly positive outlook on the company's pipeline, strategic direction, and future potential. It highlights significant market opportunities, promising clinical approaches, and a strong cash position for the near term. While it includes standard risk disclaimers, the overall tone is optimistic and forward-looking, typical of an investor presentation aimed at attracting interest and investment.

Positives

• Zura Bio possesses a pipeline of novel dual-pathway biologic candidates designed to address unmet needs in inflammatory and autoimmune (I&I) diseases.
• Tibulizumab (ZB-106) is positioned as a potential first-in-class dual-pathway biologic, uniquely targeting both BAFF for B cell regulation and IL-17A for inflammation control.
• The company has two ongoing Phase 2 clinical trials for tibulizumab in systemic sclerosis (TibuSURE) and hidradenitis suppurativa (TibuSHIELD), with topline data expected in 2026.
• Clinical precedents for separately inhibiting IL-17A or BAFF have shown efficacy in SSc, supporting the rationale for tibulizumab's dual-target approach.
• Preliminary real-world evidence for ixekizumab, a component of tibulizumab, suggests clinical benefit in TNF-experienced HS patients, showing reductions in IHS4 and improvements in DLQI scores.
• The company successfully raised $112.5 million through a private placement in 2024, providing a projected cash runway through 2027.
• Key leadership appointments in 2024, including Rob Lisicki as CEO and Dr. Kiran Nistala as CMO, strengthen the management team.
• The I&I market, particularly for conditions like psoriasis, has seen significant growth driven by mechanistic innovation, suggesting a similar opportunity for HS.

Negatives

• The company has not completed any clinical trials and has no products approved for commercial sale.
• Zura Bio has incurred significant losses since inception and expects to incur significant losses for the foreseeable future, with no assurance of achieving or sustaining profitability.
• The binding affinity data for tibulizumab's IL-17A component (Kd 2400 pM) appears weaker than other approved IL-17 inhibitors like Taltz (Kd 23 pM), Bimzelx (Kd 1.8 pM), and Cosentyx (Kd 60-90 pM), despite the text claiming 'strong binding affinity' for its IL-17A-targeting component.

Risks

• Actual results may differ materially from forward-looking statements due to various risks and uncertainties.
• The timing of key events, including study initiation and completion, and the release of clinical data, may take longer than anticipated or may not be achieved at all.
• The potential general acceptability and maintenance of Zura Bio's product candidates by regulatory authorities, payors, physicians, and patients may not be achieved.
• Zura Bio's ability to attract and retain key personnel may be challenged.
• Future operating expenses, capital requirements, and needs for additional financing may be higher than anticipated, and the company may be unable to raise such capital when needed or on acceptable terms, potentially forcing delays, reductions, or elimination of development programs or commercialization efforts.
• The company may be unable to renew existing contracts or enter into new contracts.
• Zura Bio relies on third-party contract development manufacturing organizations (CDMOs) for the manufacture of clinical materials and on contract research organizations (CROs), clinical trial sites, and other third parties to conduct its preclinical studies and clinical trials.
• Zura Bio may be unable to obtain regulatory approval for its product candidates, and there may be related restrictions or limitations on any approved products.
• The company may be unable to successfully respond to general economic and geopolitical conditions.
• Zura Bio may be unable to effectively manage growth.
• The company faces competitive pressures from other companies worldwide.
• Zura Bio may be unable to adequately protect its intellectual property rights.
• Risks and uncertainties may be amplified by health epidemics or other unanticipated global disruption events, which may continue to cause economic uncertainty.

Future Outlook

Zura Bio anticipates significant growth opportunities over the next 12 to 18 months, with multiple key milestones expected, including topline data from its Phase 2 TibuSURE (SSc) and TibuSHIELD (HS) clinical trials in Q2 2026 and Q3 2026, respectively. Pending positive data outcomes, the company plans to advance both programs into Phase 3 clinical trials. The company projects its cash runway to extend through 2027.

Management Comments

• Rob Lisicki was appointed as CEO in 2024.
• Dr. Kiran Nistala was appointed as CMO in 2024.
• Kim Davis signed the 8-K filing as Chief Operating Officer, Chief Legal Officer and Corporate Secretary.

Industry Context

Zura Bio operates within the immunology and inflammation (I&I) disease space, a market characterized by significant unmet needs and a history of growth driven by mechanistic innovation. The company's focus on dual-pathway biologics, particularly targeting IL-17 and BAFF, aligns with emerging strategies in the industry, as evidenced by combination therapies showing enhanced efficacy in other I&I conditions like ulcerative colitis. The presentation draws a parallel to the psoriasis market, which experienced substantial growth (approximately 28x) following the introduction of therapies targeting TNF, IL-17, and IL-23 pathways, suggesting a similar potential for innovation-driven growth in the hidradenitis suppurativa market.

Comparison to Industry Standards

• Approved biologics for HS, such as Humira (adalimumab, TNF inhibitor), Cosentyx (secukinumab, IL-17A inhibitor), and Bimzelx (bimekizumab, IL-17A & IL-17F inhibitor), demonstrate comparable HiSCR75 efficacy in Phase 3 trials, with placebo-adjusted deltas ranging from 6% to 21%.
• Remibrutinib (BTK inhibitor) showed a 25% HiSCR75 placebo-adjusted delta in its Phase 2 RCT for HS, suggesting that B-cell targeting mechanisms can achieve clinical outcomes and has advanced to Phase 3.
• The VEGA study in ulcerative colitis demonstrated that dual-pathway inhibition (Anti-TNF + Anti-IL23) achieved 47% clinical remission at Week 12, an incremental improvement of 22% over monotherapy (~25% remission for Anti-TNF or Anti-IL23 alone), providing clinical proof-of-concept for Zura Bio's dual-mechanism strategy.
• Tibulizumab's IL-17A-targeting component is engineered from Taltz (ixekizumab), which has an established safety and tolerability profile and has shown preliminary real-world clinical benefit in TNF-experienced HS patients (mean IHS4 score reduction from 13.6 to 9.6, DLQI improvement from 11.7 to 7.8 at Week 16).

Management Changes

Stakeholder Impact

• **Shareholders:** Potential for value creation through successful clinical development and commercialization of novel biologic candidates, but also risk of dilution from future capital raises and clinical trial failures.
• **Patients:** Potential for new, more effective treatment options for severe autoimmune and inflammatory diseases like systemic sclerosis and hidradenitis suppurativa, which currently have significant unmet needs.
• **Employees:** Continued employment and potential growth opportunities as the company advances its pipeline.
• **Creditors:** The company's cash runway through 2027 and recent capital raise indicate a stable financial position in the near term, but future capital needs are highlighted.
• **Suppliers/Partners:** Continued engagement with third-party contract development manufacturing organizations (CDMOs) and contract research organizations (CROs) for clinical material manufacturing and trial conduct.

Next Steps

• Continue recruitment for the TibuSURE Phase 2 clinical trial in systemic sclerosis (SSc).
• Continue recruitment for the TibuSHIELD Phase 2 clinical trial in hidradenitis suppurativa (HS).
• Release topline data from the TibuSURE SSc trial in Q2 2026.
• Release topline data from the TibuSHIELD HS trial in Q3 2026.
• Pending positive data outcomes, advance both tibulizumab programs into Phase 3 clinical trials.

Key Dates

Recommendation

Keywords

Zura Bio, ZURA, biologics, autoimmune diseases, inflammatory diseases, tibulizumab, ZB-106, systemic sclerosis, hidradenitis suppurativa, SSc, HS, BAFF, IL-17, clinical trials, Phase 2, biotechnology, drug development, immunology, crebankitug, ZB-168, torudokimab, ZB-880